Remove ads

Introducing the LemonFools Personal Finance Calculators

AstraZeneca PLC (AZN)

Share latest information on individual companies and hot news discussions. FTSE 350 companies only
Forum rules
No penny shares or promotional posts
idpickering
Lemon Quarter
Posts: 3850
Joined: November 4th, 2016, 5:04 pm
Has thanked: 543 times
Been thanked: 1108 times

AstraZeneca PLC (AZN)

#198202

Postby idpickering » February 1st, 2019, 3:57 pm

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxiga (dapagliflozin), after adopting a positive opinion for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D).


https://www.investegate.co.uk/astrazene ... 17558703O/

moorfield
Lemon Quarter
Posts: 1399
Joined: November 7th, 2016, 1:56 pm
Has thanked: 278 times
Been thanked: 312 times

Re: AstraZeneca - Forxiga receives positive EU CHMP opinion

#198208

Postby moorfield » February 1st, 2019, 4:12 pm

Good news (I think). :?

For the next 57 days at least, after which it becomes illegal I wonder ... :shock:

idpickering
Lemon Quarter
Posts: 3850
Joined: November 4th, 2016, 5:04 pm
Has thanked: 543 times
Been thanked: 1108 times

AstraZeneca - EMA grants PRIME eligibility for MEDI8897

#198979

Postby idpickering » February 5th, 2019, 7:20 am

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Medicines Agency (EMA) has granted access to its PRIME (PRIority MEdicines) scheme for MEDI8897, an extended half-life respiratory syncytial virus (RSV) F monoclonal antibody (mAb) being developed for the prevention of lower respiratory tract infection (LRTI) caused by RSV.



The PRIME initiative, launched by the EMA in 2016, offers early, proactive and enhanced support to developers of promising medicines to optimise development plans and accelerate evaluation so these medicines can reach patients faster. To be eligible for PRIME, medicines must target an unmet medical need and show potential benefit for patients based on early clinical data.



Mene Pangalos, Executive Vice-President, R&D BioPharmaceuticals, said: "We are excited to receive PRIME eligibility for MEDI8897, our next-generation monoclonal antibody targeting respiratory syncytial virus in infants. We will work closely with the European Medicines Agency to optimise our development plan and help us bring MEDI8897 to patients as quickly as possible."



This is the first EMA PRIME eligibility that AstraZeneca has received since the programme's initiation. It is based on the primary analysis of the Phase IIb trial to evaluate the safety and efficacy of MEDI8897, which met its primary endpoint defined as a statistically-significant reduction in the incidence of medically-attended LRTI caused by reverse transcriptase polymerase chain reaction-confirmed RSV for 150 days after dosing in healthy preterm infants. Full results from the Phase IIb trial will be presented at a forthcoming medical meeting.

https://www.investegate.co.uk/astrazene ... 00070836P/

moorfield
Lemon Quarter
Posts: 1399
Joined: November 7th, 2016, 1:56 pm
Has thanked: 278 times
Been thanked: 312 times

Re: AstraZeneca - EMA grants PRIME eligibility for MEDI8897

#199037

Postby moorfield » February 5th, 2019, 11:26 am

Thanks Ian.

More temporary good news for AZN shareholders.

52 days to go. :o

idpickering
Lemon Quarter
Posts: 3850
Joined: November 4th, 2016, 5:04 pm
Has thanked: 543 times
Been thanked: 1108 times

AstraZeneca PLC (AZN)

#199213

Postby idpickering » February 6th, 2019, 7:06 am

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Fasenra (benralizumab) for the treatment of hypereosinophilic syndrome (HES).

HES is a group of rare, potentially fatal disorders characterised by high numbers of eosinophils in blood and tissues, which can cause progressive damage to any organ in the body.1,2 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US.


https://www.investegate.co.uk/astrazene ... 00021778P/

daveh
Lemon Slice
Posts: 414
Joined: November 4th, 2016, 11:06 am
Has thanked: 23 times
Been thanked: 114 times

Re: AstraZeneca Plc (AZN)

#203623

Postby daveh » February 25th, 2019, 8:24 am

Brilinta's PHIII THEMIS trail met primary endpoint.

www.investegate.co.uk/article.aspx?id=2 ... 9749Q&fe=1

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone.


So it successfully reduced stroke and heart attack in the target population (Type 2 diabetics with coronary artery disease) compared to aspirin alone.

idpickering
Lemon Quarter
Posts: 3850
Joined: November 4th, 2016, 5:04 pm
Has thanked: 543 times
Been thanked: 1108 times

Re: AstraZeneca Plc (AZN)

#203858

Postby idpickering » February 26th, 2019, 8:20 am

Lynparza significantly delayed disease progression

Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer


https://www.investegate.co.uk/astrazene ... 00261143R/

idpickering
Lemon Quarter
Posts: 3850
Joined: November 4th, 2016, 5:04 pm
Has thanked: 543 times
Been thanked: 1108 times

Re: AstraZeneca PLC (AZN)

#204558

Postby idpickering » February 28th, 2019, 1:22 pm

This from TMF;

Retirement saving: I think AstraZeneca could help you to accumulate £1 million

The performance of AstraZeneca (LSE: AZN) has started to improve significantly in recent quarters. The FTSE 100 pharma stock has returned to growth after what has been a long and arduous journey. It has suffered from the impact of patent losses, with its financial performance having disappointed significantly in recent years.

Now, though, growth is expected to continue over the long run. As such, now could be a time to buy it at a moment when a number of FTSE 100 shares, including one that reported on Thursday, may be overvalued after the index’s strong start to 2019.


https://www.fool.co.uk/investing/2019/0 ... 1-million/

idpickering
Lemon Quarter
Posts: 3850
Joined: November 4th, 2016, 5:04 pm
Has thanked: 543 times
Been thanked: 1108 times

Re: AstraZeneca PLC (AZN)

#208325

Postby idpickering » March 18th, 2019, 7:15 am

US FDA grants saracatinib ODD for IPF

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for saracatinib, a potential new medicine for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung disease that results in scarring (fibrosis) of the lungs. Saracatinib is an inhibitor of src kinase which regulates broad cell functions including cell growth and cell differentiation.1 Saracatinib has completed Phase I development.


https://www.investegate.co.uk/astrazene ... 00050958T/


Return to “Company Share news (FTSE 350)”

Who is online

Users browsing this forum: No registered users and 1 guest